Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 7/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | CCR9 | P51686 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16619272 | 0.82 | LOXL2 (0.52) | PDCD1CD274ADORA2BLOXL2RAF1 | |
| SCHEMBL18269719 | 0.77 | GRIN1 (0.37) | PDCD1CD274GRIN1GRIN2BCCR9 | |
| SCHEMBL29938196 | 0.77 | ADORA2B (0.39) | PDCD1CD274ADORA2BKDM4EALDH1A1 | |
| SCHEMBL27112910 | 0.75 | ALDH1A1 (0.35) | ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL17886903 | 0.75 | CYP11B1 (0.40) | CYP2C9 | |
| SCHEMBL24107273 | 0.75 | GRIN1 (0.35) | GRIN1GRIN2BCCR9RAF1 | |
| SCHEMBL24732637 | 0.75 | SCN8A (0.51) | KDM4EALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL7213725 | 0.74 | CYP2A6 (0.48) | PDCD1CD274GRIN1GRIN2BRAF1 | |
| SCHEMBL2560682 | 0.74 | ADORA2A (0.43) | GRIN1GRIN2BRAF1 | |
| SCHEMBL27114394 | 0.74 | AOC3 (0.33) | LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD5, ENTPD1, SLC29A1 | PDCD1 507/4885CD274 437/4885GRIN1 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.